Efmoroctocog Alfa: A Review in Haemophilia A.

ABSTRACT: Efmoroctocog alfa (Elocta^®, Eloctate^®, Eloctate™), an extended half-life (EHL) recombinant factor VIII (rFVIII)-Fc fusion protein, is approved for the treatment and prophylaxis of bleeding in patients with haemophilia A. The efficacy of efmoroctocog alfa in the prevention and treatment of bleeding in previously treated patients (PTPs) and previously untreated patients (PUPs) with severe haemophilia A has been demonstrated in phase III studies; this includes its use in the perioperative setting (in PTPs). Furthermore, the effectiveness of efmoroctocog alfa in clinical practice has been confirmed in numerous real-world studies; compared with conventional, standard half-life (SHL) FVIII products, prophylaxis with this EHL FVIII product achieved similar or reduced bleedin

SUBMITTER: Frampton JE 

PROVIDER: S-EPMC8636404 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature